FDA approves Aducanumab, the first new Alzheimer’s disease treatment in almost two decades and the first to attack the disease process. Learn more here.
The LIAD Center is open and offering in-person programming with restrictions in place. The health and safety of our employees and families remain our top priority. We also continue to offer virtual services.
Click here to watch the video and read the article on CBS 2 NY.